Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of LDN and NAD+ in Post-COVID-19 Syndrome
NCT04604704Phase 2Completed
- Sponsor
- AgelessRx
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naltrexone and nicotinamide adenine dinucleotide in post acute COVID-19 syndrome, sponsored by AgelessRx. Primary endpoint: Reduction of fatigue in post-COVID-19 syndrome measured by Chalder Fatigue Scale at 12 weeks. Started Jan 2021; status: completed.
02
Drugs
naltrexonenicotinamide adenine dinucleotide
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT04604704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604704.